Search clinical trials for: AK104+anlotinib

Total 1539 results

Eli Lilly and Company

Completed

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Lymphoma | Carcinoma, Non-Small-Cell Lung | Solid Tumors

Japan
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Genentech, Inc.

Completed

A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

Lung Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Stage IV Ovarian Epithelial Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma... and other conditions

United States
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
Nanfang Hospital of Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Essential Tremor

China
Qingdao Central Hospital

Recruiting

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

China
Second Affiliated Hospital of Nanchang University

Unknown

Phase I Study of the Combination of Anlotinib With Gefitinib

Non-squamous Non-small Cell Lung Cancer
Eli Lilly and Company

Active, not recruiting

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (Balise)

Carcinoma, Non-Small-Cell Lung

Spain, Taiwan, United Kingdom, France, Germany, Netherlands, Korea, Republic of, Italy, Denmark
Rush University Medical Center

Terminated

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Metastatic Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Incyte Corporation

Completed

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Lung Cancer

United States
Hoffmann-La Roche
Clalit Health Services

Completed

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

Non-Squamous Non-Small Cell Lung Cancer

Israel
University Health Network, Toronto
Hoffmann-La Roche

Completed

Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) (SELECT)

Non Small Cell Lung Cancer

Canada
Ohio State University Comprehensive Cancer Center
Genentech, Inc.

Completed

OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Hoffmann-La Roche

Completed

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Italy, Belgium, Israel, Sweden, China, Hong Kong, Australia, Colombia, Romania, Germany, Ireland, Mexico, Korea, Republic of, Taiwan, Turkey, Russian Federation, Czech Republic, Hungary, Netherlands, New Zealand, Peru, Finland, Austria and more
Hoffmann-La Roche

Terminated

A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment (STAR)

Non-Squamous Non-Small Cell Lung Cancer

Romania
Hoffmann-La Roche

Completed

An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer (TEAM)

Nonsquamous Nonsmall Cell Neoplasm of Lung

Belgium, Luxembourg
Institut Claudius Regaud
Roche Pharma AG

Completed

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Head and Neck Neoplasms

France
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Spain
The Cleveland Clinic

Unknown

Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Exelixis

Completed

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital; Korean Cancer Study Group

Terminated

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Leptomeningeal Carcinomatosis

Korea, Republic of
NorthShore University HealthSystem
Northwestern University; Genentech, Inc.

Completed

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy

Prostate Cancer

United States
Grupo Gallego de Cancer de Pulmon

Unknown

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Spain
National Cancer Institute (NCI)

Terminated

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Chronic Phase Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (ENESTxtnd)

Chronic Myeloid Leukemia

Canada, Egypt, Saudi Arabia, Australia, Lebanon, South Africa, Israel, Russian Federation, Brazil, Thailand, Malaysia, Argentina, Taiwan, India, Oman, United Arab Emirates, Tunisia, Mexico, Algeria
NCIC Clinical Trials Group
Roche Pharma AG

Completed

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

Canada
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Non-Squamous Non-Small Cell Lung Cancer

Italy
Northwell Health
Genentech, Inc.

Completed

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States
Northwestern University
OSI Pharmaceuticals

Withdrawn

Erlotinib for Treatment of Psoriasis

Psoriasis

United States
Alaunos Therapeutics

Unknown

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Advanced Solid Tumors

United States
Janssen-Cilag, S.A.

Completed

PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder
Shanghai Chest Hospital

Completed

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Non Small Cell Lung Cancer

China
University of Oklahoma
OSI Pharmaceuticals

Terminated

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera (OSI-TAR-766)

Polycythemia Vera

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astellas Pharma US, Inc.

Completed

Erlotinib Prevention of Oral Cancer (EPOC)

Oral Cancer

United States
M.D. Anderson Cancer Center
United States Department of Defense

Completed

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

United States
University of Alabama at Birmingham
OSI Pharmaceuticals

Terminated

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

Pancreatic Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
SCRI Development Innovations, LLC
GlaxoSmithKline; OSI Pharmaceuticals

Completed

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Completed

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, Spain, France, Argentina, Canada, Poland
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
Michael Prados
National Cancer Institute (NCI); Genentech, Inc.

Terminated

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Adult Brain Tumors

United States

Search clinical trials for: AK104+anlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations